{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-002863","form_type":"8-K","ticker":"NVAX","cik":"0001000694","company_name":"NOVAVAX INC","filed_at":"2025-01-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:02.620741+00:00","generated_at":"2026-05-28T02:35:16.240490+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"confidence":"low","headline":"Novavax reaffirms full year 2024 guidance; presents at J.P. Morgan conference","bullets":["Reaffirmed full year 2024 financial guidance, no specific figures provided.","Preliminary expectations for combined R&D and SG&A expenses for 2025 and 2026 mentioned without numbers.","Presenting strategic updates at 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-002863","json":"https://secwatch.observer/filing/0001104659-25-002863.json","markdown":"https://secwatch.observer/filing/0001104659-25-002863.md","text":"https://secwatch.observer/filing/0001104659-25-002863.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1000694/000110465925002863/0001104659-25-002863-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1000694/000110465925002863/tm253091d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T02:35:16.240490+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}